Sacubitril/Valsartan for Blood Pressure Lowering in Non‐Dialysis‐Dependent Chronic Kidney Disease Stage 3–5 Patients With Hypertension: A Multicenter Clinical Study
ABSTRACT To assess the effectiveness and safety of Sacubitril/Valsartan in reducing blood pressure in individuals with non‐dialysis‐dependent chronic kidney disease (NDD‐CKD) Stage 3–5 complicated by hypertension. This study was a multicenter retrospective analysis conducted from March 1, 2022 to Ma...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | The Journal of Clinical Hypertension |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/jch.14969 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832576408104206336 |
|---|---|
| author | Yu Yan Xiaomin Li Juan Cao Jingyuan Cao Yao Wang Liang Wang Jirong Yu Lianhua Chen Min Yang Xinzhong Huang Lei Shen Hong Ding Manzhi Li Di Yin Linglin Jiang Liang Tang Yujia Jiang Ling Hu Jiyi Si Hui Zhang Liqin Cui Xiameng Gu Kun Hu Dongxing Mu Bicheng Liu Xiaoliang Zhang Dong Sun Xin Wan Bin Wang |
| author_facet | Yu Yan Xiaomin Li Juan Cao Jingyuan Cao Yao Wang Liang Wang Jirong Yu Lianhua Chen Min Yang Xinzhong Huang Lei Shen Hong Ding Manzhi Li Di Yin Linglin Jiang Liang Tang Yujia Jiang Ling Hu Jiyi Si Hui Zhang Liqin Cui Xiameng Gu Kun Hu Dongxing Mu Bicheng Liu Xiaoliang Zhang Dong Sun Xin Wan Bin Wang |
| author_sort | Yu Yan |
| collection | DOAJ |
| description | ABSTRACT To assess the effectiveness and safety of Sacubitril/Valsartan in reducing blood pressure in individuals with non‐dialysis‐dependent chronic kidney disease (NDD‐CKD) Stage 3–5 complicated by hypertension. This study was a multicenter retrospective analysis conducted from March 1, 2022 to March 31, 2024, involving adult patients with NDD‐CKD Stage 3–5 and hypertension, who received Sacubitril/Valsartan either as a monotherapy or in addition to current antihypertensive treatments that were insufficient. The main outcomes measured were blood pressure control, changes in blood pressure and laboratory parameters within 8 weeks post‐treatment initiation, and incidence of adverse events. The study included a total of 459 individuals with NDD‐CKD Stage 3–5 and hypertension. At the study endpoint, mean systolic blood pressure, diastolic blood pressure, and pulse pressure were markedly reduced compared to baseline (all p < 0.001). The average blood pressure reductions were 12.17 (4.66, 22.00), 6.00 (0.67, 12.66), and 6.67 (0.08, 14.00) mmHg, respectively. Throughout the study period, 96 patients (20.92%) with NDD‐CKD Stage 3–5 developed worsening renal function, 15 patients (3.27%) developed hyperkalemia, and 49 patients (10.68%) experienced symptomatic hypotension. Overall, there were no significant differences in the changes in serum creatinine, estimated glomerular filtration rate, and serum potassium before and after treatment (p = 0.28, p = 0.91, p = 0.61, respectively). Sacubitril/Valsartan significantly lowers blood pressure in patients with NDD‐CKD Stage 3–5 complicated by hypertension, with good safety profiles. Trial Registration: ClinicalTrials.gov identifier: ChiCTR2400086079 |
| format | Article |
| id | doaj-art-5cec653290bd452e89526b9e9fc1c3a2 |
| institution | Kabale University |
| issn | 1524-6175 1751-7176 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Journal of Clinical Hypertension |
| spelling | doaj-art-5cec653290bd452e89526b9e9fc1c3a22025-01-31T05:38:37ZengWileyThe Journal of Clinical Hypertension1524-61751751-71762025-01-01271n/an/a10.1111/jch.14969Sacubitril/Valsartan for Blood Pressure Lowering in Non‐Dialysis‐Dependent Chronic Kidney Disease Stage 3–5 Patients With Hypertension: A Multicenter Clinical StudyYu Yan0Xiaomin Li1Juan Cao2Jingyuan Cao3Yao Wang4Liang Wang5Jirong Yu6Lianhua Chen7Min Yang8Xinzhong Huang9Lei Shen10Hong Ding11Manzhi Li12Di Yin13Linglin Jiang14Liang Tang15Yujia Jiang16Ling Hu17Jiyi Si18Hui Zhang19Liqin Cui20Xiameng Gu21Kun Hu22Dongxing Mu23Bicheng Liu24Xiaoliang Zhang25Dong Sun26Xin Wan27Bin Wang28Department of Nephrology Southeast University Zhongda Hospital Southeast University School of Medicine Nanjing ChinaDepartment of Pharmacy Zhongda Hospital Southeast University Nanjing ChinaDepartment of Nephrology Taixing People's Hospital Affiliated to Yangzhou University Taizhou ChinaDepartment of Nephrology The Affiliated Taizhou People's Hospital of Nanjing Medical University Taizhou School of Clinical Medicine Nanjing Medical University Taizhou ChinaDepartment of Nephrology The Affiliated Hospital of Yangzhou University Yangzhou University Yangzhou ChinaDepartment of Nephrology The Affiliated Wuxi People's Hospital of Nanjing Medical University Wuxi ChinaDepartment of Nephrology Jiangbei Campus Zhongda Hospital Southeast University Nanjing ChinaDepartment of Nephrology Huai'an First People's Hospital Nanjing Medical University Huai'an ChinaDepartment of Nephrology The Third Affiliated Hospital of Soochow University Changzhou ChinaDepartment of Nephrology Affiliated Hospital of Nantong University Nantong ChinaDepartment of Nephrology The First Affiliated Hospital of Soochow University Suzhou ChinaDepartment of Nephrology People's Hospital of Yangzhong City Zhenjiang ChinaDepartment of Nephrology Affiliated Hospital of Xuzhou Medical University Xuzhou ChinaDepartment of Nephrology Taixing People's Hospital Affiliated to Yangzhou University Taizhou ChinaDepartment of Nephrology Nanjing First Hospital Nanjing Medical University Nanjing ChinaDepartment of Cardiology The Affiliated Taizhou People's Hospital of Nanjing Medical University Taizhou School of Clinical Medicine Nanjing Medical University Taizhou ChinaDepartment of Nephrology The Affiliated Hospital of Yangzhou University Yangzhou University Yangzhou ChinaDepartment of Nephrology The Affiliated Wuxi People's Hospital of Nanjing Medical University Wuxi ChinaDepartment of Nephrology Jiangbei Campus Zhongda Hospital Southeast University Nanjing ChinaDepartment of Nephrology Huai'an First People's Hospital Nanjing Medical University Huai'an ChinaDepartment of Nephrology The Third Affiliated Hospital of Soochow University Changzhou ChinaDepartment of Nephrology Affiliated Hospital of Nantong University Nantong ChinaDepartment of Nephrology The First Affiliated Hospital of Soochow University Suzhou ChinaDepartment of Nephrology People's Hospital of Yangzhong City Zhenjiang ChinaDepartment of Nephrology Southeast University Zhongda Hospital Southeast University School of Medicine Nanjing ChinaDepartment of Nephrology Southeast University Zhongda Hospital Southeast University School of Medicine Nanjing ChinaDepartment of Nephrology Affiliated Hospital of Xuzhou Medical University Xuzhou ChinaDepartment of Nephrology Nanjing First Hospital Nanjing Medical University Nanjing ChinaDepartment of Nephrology Southeast University Zhongda Hospital Southeast University School of Medicine Nanjing ChinaABSTRACT To assess the effectiveness and safety of Sacubitril/Valsartan in reducing blood pressure in individuals with non‐dialysis‐dependent chronic kidney disease (NDD‐CKD) Stage 3–5 complicated by hypertension. This study was a multicenter retrospective analysis conducted from March 1, 2022 to March 31, 2024, involving adult patients with NDD‐CKD Stage 3–5 and hypertension, who received Sacubitril/Valsartan either as a monotherapy or in addition to current antihypertensive treatments that were insufficient. The main outcomes measured were blood pressure control, changes in blood pressure and laboratory parameters within 8 weeks post‐treatment initiation, and incidence of adverse events. The study included a total of 459 individuals with NDD‐CKD Stage 3–5 and hypertension. At the study endpoint, mean systolic blood pressure, diastolic blood pressure, and pulse pressure were markedly reduced compared to baseline (all p < 0.001). The average blood pressure reductions were 12.17 (4.66, 22.00), 6.00 (0.67, 12.66), and 6.67 (0.08, 14.00) mmHg, respectively. Throughout the study period, 96 patients (20.92%) with NDD‐CKD Stage 3–5 developed worsening renal function, 15 patients (3.27%) developed hyperkalemia, and 49 patients (10.68%) experienced symptomatic hypotension. Overall, there were no significant differences in the changes in serum creatinine, estimated glomerular filtration rate, and serum potassium before and after treatment (p = 0.28, p = 0.91, p = 0.61, respectively). Sacubitril/Valsartan significantly lowers blood pressure in patients with NDD‐CKD Stage 3–5 complicated by hypertension, with good safety profiles. Trial Registration: ClinicalTrials.gov identifier: ChiCTR2400086079https://doi.org/10.1111/jch.14969chronic kidney diseaseefficacyhypertensionsacubitril/valsartansafety |
| spellingShingle | Yu Yan Xiaomin Li Juan Cao Jingyuan Cao Yao Wang Liang Wang Jirong Yu Lianhua Chen Min Yang Xinzhong Huang Lei Shen Hong Ding Manzhi Li Di Yin Linglin Jiang Liang Tang Yujia Jiang Ling Hu Jiyi Si Hui Zhang Liqin Cui Xiameng Gu Kun Hu Dongxing Mu Bicheng Liu Xiaoliang Zhang Dong Sun Xin Wan Bin Wang Sacubitril/Valsartan for Blood Pressure Lowering in Non‐Dialysis‐Dependent Chronic Kidney Disease Stage 3–5 Patients With Hypertension: A Multicenter Clinical Study The Journal of Clinical Hypertension chronic kidney disease efficacy hypertension sacubitril/valsartan safety |
| title | Sacubitril/Valsartan for Blood Pressure Lowering in Non‐Dialysis‐Dependent Chronic Kidney Disease Stage 3–5 Patients With Hypertension: A Multicenter Clinical Study |
| title_full | Sacubitril/Valsartan for Blood Pressure Lowering in Non‐Dialysis‐Dependent Chronic Kidney Disease Stage 3–5 Patients With Hypertension: A Multicenter Clinical Study |
| title_fullStr | Sacubitril/Valsartan for Blood Pressure Lowering in Non‐Dialysis‐Dependent Chronic Kidney Disease Stage 3–5 Patients With Hypertension: A Multicenter Clinical Study |
| title_full_unstemmed | Sacubitril/Valsartan for Blood Pressure Lowering in Non‐Dialysis‐Dependent Chronic Kidney Disease Stage 3–5 Patients With Hypertension: A Multicenter Clinical Study |
| title_short | Sacubitril/Valsartan for Blood Pressure Lowering in Non‐Dialysis‐Dependent Chronic Kidney Disease Stage 3–5 Patients With Hypertension: A Multicenter Clinical Study |
| title_sort | sacubitril valsartan for blood pressure lowering in non dialysis dependent chronic kidney disease stage 3 5 patients with hypertension a multicenter clinical study |
| topic | chronic kidney disease efficacy hypertension sacubitril/valsartan safety |
| url | https://doi.org/10.1111/jch.14969 |
| work_keys_str_mv | AT yuyan sacubitrilvalsartanforbloodpressureloweringinnondialysisdependentchronickidneydiseasestage35patientswithhypertensionamulticenterclinicalstudy AT xiaominli sacubitrilvalsartanforbloodpressureloweringinnondialysisdependentchronickidneydiseasestage35patientswithhypertensionamulticenterclinicalstudy AT juancao sacubitrilvalsartanforbloodpressureloweringinnondialysisdependentchronickidneydiseasestage35patientswithhypertensionamulticenterclinicalstudy AT jingyuancao sacubitrilvalsartanforbloodpressureloweringinnondialysisdependentchronickidneydiseasestage35patientswithhypertensionamulticenterclinicalstudy AT yaowang sacubitrilvalsartanforbloodpressureloweringinnondialysisdependentchronickidneydiseasestage35patientswithhypertensionamulticenterclinicalstudy AT liangwang sacubitrilvalsartanforbloodpressureloweringinnondialysisdependentchronickidneydiseasestage35patientswithhypertensionamulticenterclinicalstudy AT jirongyu sacubitrilvalsartanforbloodpressureloweringinnondialysisdependentchronickidneydiseasestage35patientswithhypertensionamulticenterclinicalstudy AT lianhuachen sacubitrilvalsartanforbloodpressureloweringinnondialysisdependentchronickidneydiseasestage35patientswithhypertensionamulticenterclinicalstudy AT minyang sacubitrilvalsartanforbloodpressureloweringinnondialysisdependentchronickidneydiseasestage35patientswithhypertensionamulticenterclinicalstudy AT xinzhonghuang sacubitrilvalsartanforbloodpressureloweringinnondialysisdependentchronickidneydiseasestage35patientswithhypertensionamulticenterclinicalstudy AT leishen sacubitrilvalsartanforbloodpressureloweringinnondialysisdependentchronickidneydiseasestage35patientswithhypertensionamulticenterclinicalstudy AT hongding sacubitrilvalsartanforbloodpressureloweringinnondialysisdependentchronickidneydiseasestage35patientswithhypertensionamulticenterclinicalstudy AT manzhili sacubitrilvalsartanforbloodpressureloweringinnondialysisdependentchronickidneydiseasestage35patientswithhypertensionamulticenterclinicalstudy AT diyin sacubitrilvalsartanforbloodpressureloweringinnondialysisdependentchronickidneydiseasestage35patientswithhypertensionamulticenterclinicalstudy AT linglinjiang sacubitrilvalsartanforbloodpressureloweringinnondialysisdependentchronickidneydiseasestage35patientswithhypertensionamulticenterclinicalstudy AT liangtang sacubitrilvalsartanforbloodpressureloweringinnondialysisdependentchronickidneydiseasestage35patientswithhypertensionamulticenterclinicalstudy AT yujiajiang sacubitrilvalsartanforbloodpressureloweringinnondialysisdependentchronickidneydiseasestage35patientswithhypertensionamulticenterclinicalstudy AT linghu sacubitrilvalsartanforbloodpressureloweringinnondialysisdependentchronickidneydiseasestage35patientswithhypertensionamulticenterclinicalstudy AT jiyisi sacubitrilvalsartanforbloodpressureloweringinnondialysisdependentchronickidneydiseasestage35patientswithhypertensionamulticenterclinicalstudy AT huizhang sacubitrilvalsartanforbloodpressureloweringinnondialysisdependentchronickidneydiseasestage35patientswithhypertensionamulticenterclinicalstudy AT liqincui sacubitrilvalsartanforbloodpressureloweringinnondialysisdependentchronickidneydiseasestage35patientswithhypertensionamulticenterclinicalstudy AT xiamenggu sacubitrilvalsartanforbloodpressureloweringinnondialysisdependentchronickidneydiseasestage35patientswithhypertensionamulticenterclinicalstudy AT kunhu sacubitrilvalsartanforbloodpressureloweringinnondialysisdependentchronickidneydiseasestage35patientswithhypertensionamulticenterclinicalstudy AT dongxingmu sacubitrilvalsartanforbloodpressureloweringinnondialysisdependentchronickidneydiseasestage35patientswithhypertensionamulticenterclinicalstudy AT bichengliu sacubitrilvalsartanforbloodpressureloweringinnondialysisdependentchronickidneydiseasestage35patientswithhypertensionamulticenterclinicalstudy AT xiaoliangzhang sacubitrilvalsartanforbloodpressureloweringinnondialysisdependentchronickidneydiseasestage35patientswithhypertensionamulticenterclinicalstudy AT dongsun sacubitrilvalsartanforbloodpressureloweringinnondialysisdependentchronickidneydiseasestage35patientswithhypertensionamulticenterclinicalstudy AT xinwan sacubitrilvalsartanforbloodpressureloweringinnondialysisdependentchronickidneydiseasestage35patientswithhypertensionamulticenterclinicalstudy AT binwang sacubitrilvalsartanforbloodpressureloweringinnondialysisdependentchronickidneydiseasestage35patientswithhypertensionamulticenterclinicalstudy |